NR565 WEEK 8 FINAL EXAM: COMPLETE 100
PRACTICE QUESTIONS | ADVANCED
PHARMACOLOGY FUNDAMENTALS | 100%
PASS GUARANTEED | GRADED A+
CORE DOMAINS
• Pharmacokinetics and Pharmacodynamics
• Endocrine Pharmacology (Diabetes, Thyroid)
• Respiratory Pharmacology (Asthma, COPD)
• Gastrointestinal Pharmacology
• Pain Management and Opioid Pharmacology
• Cardiovascular Pharmacology
• Antimicrobial Pharmacology
• Neurological and Psychiatric Pharmacology
• Medication Safety and Prescribing Principles
• Drug Interactions and Adverse Effects
INTRODUCTION
This comprehensive 100-question practice examination is designed to assess
and reinforce your knowledge of advanced pharmacology fundamentals
essential for safe and effective prescribing. The exam evaluates your
understanding of pharmacokinetics, pharmacodynamics, drug classifications,
adverse effects, drug interactions, and clinical application of pharmacological
principles across multiple body systems. It features a blend of multiple-choice
questions, select-all-that-apply (SATA) items, and case-based application
questions to measure critical thinking and clinical decision-making. Success on
this practice examination indicates readiness for the NR565 Week 8 Final Exam
and advanced pharmacology competency.
QUESTIONS 1-100
1. Bioavailability is defined as:
A. The amount of drug administered
B. The percentage of drug that reaches systemic circulation unchanged
,C. The rate of drug metabolism
D. The volume of drug distribution
B. The percentage of drug that reaches systemic circulation unchanged
RATIONALE: Bioavailability refers to the fraction of an administered dose
of a drug that reaches systemic circulation in its unchanged form. It is
influenced by factors such as first-pass metabolism, drug formulation, and
route of administration. Intravenous administration has 100% bioavailability.
2. The half-life (t½) of a drug is clinically important because it determines:
A. The time to reach steady state
B. The frequency of dosing
C. The time required for drug elimination
D. All of the above
D. All of the above
RATIONALE: Half-life determines the time required for a drug to reach
steady state (approximately 4-5 half-lives), the appropriate dosing interval,
and the time required for drug elimination. Understanding half-life is essential
for safe prescribing and monitoring.
3. A weak acid drug would be best absorbed in which of the following
environments?
A. The stomach (pH 1.5-3.5)
B. The small intestine (pH 6-8)
C. The colon (pH 5-7)
D. The blood (pH 7.35-7.45)
A. The stomach (pH 1.5-3.5)
RATIONALE: Weak acids are better absorbed in acidic environments
because they remain non-ionized and can cross lipid membranes. The
stomach's acidic pH favors the absorption of weak acids. Weak bases are
better absorbed in the more alkaline environment of the small intestine.
4. Pharmacodynamics is best defined as:
A. The study of drug movement through the body
B. What the drug does to the body
C. The study of drug metabolism
D. The process of drug excretion
, B. What the drug does to the body
RATIONALE: Pharmacodynamics is the study of the biochemical and
physiological effects of drugs on the body and the mechanisms of drug action,
including receptor binding, dose-response relationships, and therapeutic and
adverse effects.
5. A patient with type 2 diabetes has an HbA1c of 10.2% on maximal
metformin therapy. Which of the following would be the most appropriate
next step?
A. Add a sulfonylurea
B. Add a GLP-1 receptor agonist
C. Add a DPP-4 inhibitor
D. Add a SGLT2 inhibitor
E. Any of the above may be appropriate depending on patient factors
E. Any of the above may be appropriate depending on patient factors
RATIONALE: When glycemic targets are not met with metformin alone, a
second agent can be added. The choice among sulfonylureas, GLP-1 receptor
agonists, DPP-4 inhibitors, and SGLT2 inhibitors depends on patient-specific
factors such as cardiovascular risk, renal function, cost, side effect profile, and
patient preference.
6. Metformin is contraindicated in patients with which of the following?
A. eGFR < 60 mL/min/1.73m²
B. eGFR < 45 mL/min/1.73m²
C. eGFR < 30 mL/min/1.73m²
D. eGFR < 15 mL/min/1.73m²
C. eGFR < 30 mL/min/1.73m²
RATIONALE: Metformin is contraindicated in patients with an eGFR < 30
mL/min/1.73m² due to the increased risk of lactic acidosis. An eGFR between
30-45 is a precaution and may require dose reduction. Metformin should be
held in patients with acute kidney injury or conditions that predispose to lactic
acidosis.
7. Which of the following insulins is classified as rapid-acting?
A. Insulin glargine
B. Insulin NPH
, C. Insulin lispro
D. Insulin regular
C. Insulin lispro
RATIONALE: Insulin lispro is a rapid-acting insulin with an onset of 15-30
minutes. Insulin glargine is long-acting, Insulin NPH is intermediate-acting, and
Insulin regular is short-acting. Rapid-acting insulins are typically administered
immediately before meals to control postprandial glucose.
8. The most common adverse effect of sulfonylureas is:
A. Weight gain
B. Hypoglycemia
C. Gastrointestinal upset
D. Nephrotoxicity
B. Hypoglycemia
RATIONALE: Sulfonylureas increase insulin secretion from the pancreas,
which can lead to hypoglycemia. This is especially concerning in older adults,
patients with renal impairment, or those who skip meals. Weight gain is also a
common side effect, but hypoglycemia is the most significant safety concern.
9. Levothyroxine should be taken:
A. With food to reduce GI upset
B. On an empty stomach
C. With a high-fat meal
D. At bedtime with a snack
B. On an empty stomach
RATIONALE: Levothyroxine should be taken on an empty stomach,
typically 30-60 minutes before breakfast, to enhance absorption. Food,
especially calcium and iron supplements, can significantly reduce absorption.
Consistency in administration is important for maintaining stable TSH levels.
10. Which laboratory test is the primary monitoring parameter for
levothyroxine therapy?
A. Free T3
B. TSH
C. Total T4
D. Reverse T3
PRACTICE QUESTIONS | ADVANCED
PHARMACOLOGY FUNDAMENTALS | 100%
PASS GUARANTEED | GRADED A+
CORE DOMAINS
• Pharmacokinetics and Pharmacodynamics
• Endocrine Pharmacology (Diabetes, Thyroid)
• Respiratory Pharmacology (Asthma, COPD)
• Gastrointestinal Pharmacology
• Pain Management and Opioid Pharmacology
• Cardiovascular Pharmacology
• Antimicrobial Pharmacology
• Neurological and Psychiatric Pharmacology
• Medication Safety and Prescribing Principles
• Drug Interactions and Adverse Effects
INTRODUCTION
This comprehensive 100-question practice examination is designed to assess
and reinforce your knowledge of advanced pharmacology fundamentals
essential for safe and effective prescribing. The exam evaluates your
understanding of pharmacokinetics, pharmacodynamics, drug classifications,
adverse effects, drug interactions, and clinical application of pharmacological
principles across multiple body systems. It features a blend of multiple-choice
questions, select-all-that-apply (SATA) items, and case-based application
questions to measure critical thinking and clinical decision-making. Success on
this practice examination indicates readiness for the NR565 Week 8 Final Exam
and advanced pharmacology competency.
QUESTIONS 1-100
1. Bioavailability is defined as:
A. The amount of drug administered
B. The percentage of drug that reaches systemic circulation unchanged
,C. The rate of drug metabolism
D. The volume of drug distribution
B. The percentage of drug that reaches systemic circulation unchanged
RATIONALE: Bioavailability refers to the fraction of an administered dose
of a drug that reaches systemic circulation in its unchanged form. It is
influenced by factors such as first-pass metabolism, drug formulation, and
route of administration. Intravenous administration has 100% bioavailability.
2. The half-life (t½) of a drug is clinically important because it determines:
A. The time to reach steady state
B. The frequency of dosing
C. The time required for drug elimination
D. All of the above
D. All of the above
RATIONALE: Half-life determines the time required for a drug to reach
steady state (approximately 4-5 half-lives), the appropriate dosing interval,
and the time required for drug elimination. Understanding half-life is essential
for safe prescribing and monitoring.
3. A weak acid drug would be best absorbed in which of the following
environments?
A. The stomach (pH 1.5-3.5)
B. The small intestine (pH 6-8)
C. The colon (pH 5-7)
D. The blood (pH 7.35-7.45)
A. The stomach (pH 1.5-3.5)
RATIONALE: Weak acids are better absorbed in acidic environments
because they remain non-ionized and can cross lipid membranes. The
stomach's acidic pH favors the absorption of weak acids. Weak bases are
better absorbed in the more alkaline environment of the small intestine.
4. Pharmacodynamics is best defined as:
A. The study of drug movement through the body
B. What the drug does to the body
C. The study of drug metabolism
D. The process of drug excretion
, B. What the drug does to the body
RATIONALE: Pharmacodynamics is the study of the biochemical and
physiological effects of drugs on the body and the mechanisms of drug action,
including receptor binding, dose-response relationships, and therapeutic and
adverse effects.
5. A patient with type 2 diabetes has an HbA1c of 10.2% on maximal
metformin therapy. Which of the following would be the most appropriate
next step?
A. Add a sulfonylurea
B. Add a GLP-1 receptor agonist
C. Add a DPP-4 inhibitor
D. Add a SGLT2 inhibitor
E. Any of the above may be appropriate depending on patient factors
E. Any of the above may be appropriate depending on patient factors
RATIONALE: When glycemic targets are not met with metformin alone, a
second agent can be added. The choice among sulfonylureas, GLP-1 receptor
agonists, DPP-4 inhibitors, and SGLT2 inhibitors depends on patient-specific
factors such as cardiovascular risk, renal function, cost, side effect profile, and
patient preference.
6. Metformin is contraindicated in patients with which of the following?
A. eGFR < 60 mL/min/1.73m²
B. eGFR < 45 mL/min/1.73m²
C. eGFR < 30 mL/min/1.73m²
D. eGFR < 15 mL/min/1.73m²
C. eGFR < 30 mL/min/1.73m²
RATIONALE: Metformin is contraindicated in patients with an eGFR < 30
mL/min/1.73m² due to the increased risk of lactic acidosis. An eGFR between
30-45 is a precaution and may require dose reduction. Metformin should be
held in patients with acute kidney injury or conditions that predispose to lactic
acidosis.
7. Which of the following insulins is classified as rapid-acting?
A. Insulin glargine
B. Insulin NPH
, C. Insulin lispro
D. Insulin regular
C. Insulin lispro
RATIONALE: Insulin lispro is a rapid-acting insulin with an onset of 15-30
minutes. Insulin glargine is long-acting, Insulin NPH is intermediate-acting, and
Insulin regular is short-acting. Rapid-acting insulins are typically administered
immediately before meals to control postprandial glucose.
8. The most common adverse effect of sulfonylureas is:
A. Weight gain
B. Hypoglycemia
C. Gastrointestinal upset
D. Nephrotoxicity
B. Hypoglycemia
RATIONALE: Sulfonylureas increase insulin secretion from the pancreas,
which can lead to hypoglycemia. This is especially concerning in older adults,
patients with renal impairment, or those who skip meals. Weight gain is also a
common side effect, but hypoglycemia is the most significant safety concern.
9. Levothyroxine should be taken:
A. With food to reduce GI upset
B. On an empty stomach
C. With a high-fat meal
D. At bedtime with a snack
B. On an empty stomach
RATIONALE: Levothyroxine should be taken on an empty stomach,
typically 30-60 minutes before breakfast, to enhance absorption. Food,
especially calcium and iron supplements, can significantly reduce absorption.
Consistency in administration is important for maintaining stable TSH levels.
10. Which laboratory test is the primary monitoring parameter for
levothyroxine therapy?
A. Free T3
B. TSH
C. Total T4
D. Reverse T3
